Two Rizatriptan Prescribing Portions for Treatment of Migraine
Completed
Merck Sharp & Dohme Corp.
Phase 4
2006-12-01
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9
rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit
(FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of
migraine per month.
Two Rizatriptan Prescribing Portions for Treatment of Migraine
Completed
Clinvest
Phase 4
2006-12-01
The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9
rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit
(FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of
migraine per month.
Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Completed
Merck Sharp & Dohme Corp.
Phase 3
2007-04-01
The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with
caffeine for treating acute attacks of migraine.
Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will
be dispensed one box containing 3 packets of study medication labeled for Headache #1,
Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt
placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing
placebo (sugar).
One headache will be treated with a combination of Maxalt 10mg MLT and caffeine.
Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule
containing placebo.
A third headache will be treated with just placebo.
Neither the subject, the study coordinator, or your study doctor will know in which order you
will receive the three different treatments. This information is available in case of
emergency.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
